C WorldWide Group’s Karyopharm Therapeutics KPTI Stock Holding History

C WorldWide Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$977K	Hold	100,000	–	–	0.02%	85
2026 Q1	$557K	Hold	100,000	–	–	0.01%	92
2025 Q4	$736K	Hold	100,000	–	–	0.01%	93
2025 Q3	$654K	Hold	100,000	–	–	0.01%	92
2025 Q2	$431K	Hold	100,000	–	–	0.01%	93
2025 Q1	$374K	Hold	100,000	–	–	﹤0.01%	92
2024 Q4	$1.01M	Hold	100,000	–	–	0.01%	84
2024 Q3	$1.25M	Hold	100,000	–	–	0.01%	83
2024 Q2	$1.3M	Hold	100,000	–	–	0.01%	84
2024 Q1	$2.27M	Hold	100,000	–	–	0.03%	71
2023 Q4	$1.3M	Hold	100,000	–	–	0.02%	80
2023 Q3	$2.01M	Hold	100,000	–	–	0.03%	74
2023 Q2	$2.69M	Hold	100,000	–	–	0.03%	71
2023 Q1	$5.83M	Hold	100,000	–	–	0.08%	66
2022 Q4	$5.1M	Hold	100,000	–	–	0.07%	57
2022 Q3	$8.19M	Hold	100,000	–	–	0.11%	48
2022 Q2	$6.76M	Hold	100,000	–	–	0.08%	52
2022 Q1	$11.1M	Hold	100,000	–	–	0.12%	45
2021 Q4	$9.64M	Buy	100,000 +20,000	+25%	+$1.99M	0.09%	49
2021 Q3	$6.98M	Hold	80,000	–	–	0.07%	57
2021 Q2	$12.4M	Hold	80,000	–	–	0.13%	46
2021 Q1	$12.6M	Buy	80,000 +40,000	+100%	+$8.43M	0.12%	51
2020 Q4	$9.29M	Buy	+40,000	New	+$9.27M	0.09%	56
2018 Q4	–	Sell	-1,217	Closed	-$311K	–	128
2018 Q3	$311K	Buy	1,217 +176	+17%	+$48.7K	﹤0.01%	121
2018 Q2	$265K	Hold	1,041	–	–	﹤0.01%	119
2018 Q1	$210K	Sell	1,041 -29	-3%	-$5.78K	﹤0.01%	118
2017 Q4	$154K	Sell	1,070 -164	-13%	-$26.3K	﹤0.01%	120
2017 Q3	$203K	Buy	1,234 +189	+18%	+$27.1K	﹤0.01%	122
2017 Q2	$142K	Sell	1,045 -84	-7%	-$12.4K	﹤0.01%	126
2017 Q1	$217K	Buy	1,129 +262	+30%	+$42.1K	﹤0.01%	119
2016 Q4	$122K	Buy	+867	New	+$117K	﹤0.01%	123

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

C WorldWide Group's KPTI Position: Q2 2026 in Review

C WorldWide Group held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 100,000 shares worth $977K. The position accounts for 0.02% of the portfolio, ranked #85.

C WorldWide Group first reported a position in KPTI in Q4 2016 and has held it in 31 quarters since. The position peaked at $12.6M in Q1 2021. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

C WorldWide Group held 100,000 shares of Karyopharm Therapeutics worth $977K as of Q2 2026.
C WorldWide Group left its Karyopharm Therapeutics share count unchanged in Q2 2026.
Karyopharm Therapeutics made up 0.02% of C WorldWide Group's portfolio in Q2 2026, its #85 holding.
C WorldWide Group first reported a position in Karyopharm Therapeutics in Q4 2016 and has held it in 31 quarters since.
C WorldWide Group's Karyopharm Therapeutics position peaked at $12.6M in Q1 2021.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on C WorldWide Group's 13F filing for Q2 2026, filed 4 Aug 2026.